Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | GANAB | Q14697 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21085113 | 0.82 | TP53 (0.31) | TP53 | |
| SCHEMBL8238840 | 0.82 | — | — | |
| SCHEMBL1543623 | 0.82 | SHBG (0.46) | SHBGTP53GBA1GANABKDM4E | |
| SCHEMBL8236066 | 0.82 | — | — | |
| SCHEMBL126585 | 0.82 | — | — | |
| SCHEMBL21085128 | 0.79 | SHBG (0.35) | SHBGTP53KDM4EGMNNLMNA | |
| SCHEMBL21085087 | 0.79 | GAA (0.34) | — | |
| SCHEMBL8488890 | 0.78 | TP53 (0.34) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL130751 | 0.77 | — | — | |
| SCHEMBL16621837 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-1628968-A4 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1628968-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004094404-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | GPR119, IAPP, DPP4 | SHBG 931/4885TP53 3795/4885GBA1 239/4885 |
| US-10759749-B2 | Therapeutic agent for diabetes | GPR119, IAPP, DPP4 | SHBG 207/4885TP53 2642/4885GBA1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.